As the world continues to adapt to the global public health situation, cancer immunotherapy drug developers are still actively seeking external partners that can provide solutions to the challenges they are facing as they aim to advance neoantigen targeting immunotherapies.
The 5th Neoantigen Summit Europe offers a unique opportunity to collaborate with key industry decision-makers in the space, capitalise on the market share early, cement your position as an industry leader and support the industry growth of neoantigen identification, clinical trial successes, and the best adjuvants to elicit a strong, profound immune response among a host of other services.
We’ll work with you to build a bespoke partnership package focused on making valuable connections and generating actionable leads to ensure you meet your 2022 commercial objectives.
Who Will You Meet?
With advanced access to the attendee list and the ability to invite stakeholders dedicated to advancing cancer vaccines, we will help you organise pre-scheduled 121 meetings with individuals key to your business development objectives so you can start the conference ready to maximise every minute.
What the Industry Is Looking For?
Take advantage of our carefully compiled audience of industry professionals and maximise your opportunity to form long-lasting relationships with organisations specifically seeking solutions in neoantigen identification and the best adjuvants to elicit a strong, profound immune response and peptide manufacturers among a host of other services.
What Can the 5th Neoantigen Summit Europe Do for You?
Generate leads with senior-level decision-makers from leading pharma and biotech companies. Secure a branding or speaking opportunity to demonstrate thought leadership, drive brand exposure and differentiate yourself from
competitors. Secure an exhibition booth to showcase your expertise in person and educate the industry on how you can support their efforts.